Quick Answer
Inhibrx Biosciences, Inc. reported Long-Term Debt of $100.56 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $100.56M | — |
| 2024 | $0.00 | -100.0% |
| 2023 | $206.97M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $99.92M | — | +0.6% |
| June 30, 2025 | $99.28M | — | +0.6% |
| March 31, 2025 | $98.65M | — | — |
| December 31, 2024 | $0.00 | -100.0% | — |
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | — | -100.0% |
| December 31, 2023 | $206.97M | — | — |
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s long-term debt has declined by 51.4% (from $206.97 million to $100.56 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: